← 返回

TIL 治疗的近期临床研究与技术发展

英文原题:Recent clinical researches and technological development in TIL therapy.

查看英文原题

Recent clinical researches and technological development in TIL therapy.

PubMed 2024/09/12(内容时间) Cancer Immunol Immunother Q1 · IF 5.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

TIL(肿瘤浸润淋巴细胞)疗法代表了实体瘤治疗领域的一项突破性进展,凭借高缓解率和长期总生存期,为患者及其家庭带来了新的希望。TIL疗法包括从患者肿瘤组织中提取免疫细胞,在体外扩增,然后回输到患者体内,以靶向并消灭癌细胞。这一革命性方法利用了免疫系统的力量来对抗癌症,与CAR-T 和TCR疗法一起开启了基于T细胞的疗法新时代。在这篇综合综述中,我们旨在通过深入探讨基础与临床研究的最新进展,阐明TIL疗法的显著潜力。我们重点介绍TIL疗法作为一种重要免疫治疗策略的不断演变格局、其多方面应用以及有前景的结局。此外,我们探讨TIL疗法的未来前景、下一代TIL以及联合治疗,以克服TIL疗法的局限性并提高其临床疗效。

展开英文摘要原文

Tumor-infiltrating lymphocyte (TIL) therapy represents a groundbreaking advancement in the solid cancer treatment, offering new hope to patients and their families with high response rates and long overall survival. TIL therapy involves extracting immune cells from a patient's tumor tissue, expanding them ex vivo, and infusing them back into the patient to target and eliminate cancer cells.

This revolutionary approach harnesses the power of the immune system to combat cancers, ushering in a new era of T cell-based therapies along with CAR-T and TCR-therapies. In this comprehensive review, we aim to elucidate the remarkable potential of TIL therapy by delving into recent advancements in basic and clinical researches.

We highlight on the evolving landscape of TIL therapy as a prominent immunotherapeutic strategy, its multifaceted applications, and the promising outcomes.

Additionally, we explore the future horizons of TIL therapy, next-generation TILs, and combination therapy, to overcome the limitations and improve clinical efficacy of TIL therapy.

论文信息

作者
Matsueda S、Chen L、Li H、Yao H、Yu F
单位
Fresh Wind Biotechnologies USA Inc, 4502 Riverstone Blvd, STE1104, Missouri City, TX, 77459, USA. satoko.matsueda@freshwindbiotech.com.United States
文献类型
综述
期刊
Cancer immunology, immunotherapy : CII2024 Sep 12
原文标识
PubMed 39264449 · DOI 10.1007/s00262-024-03793-4